Payment overview · 2025
General Payments
$1,012.85
28 reported records · 6 companies
Healthcare provider profile · identity verified
Jose A Curet Ramos
Allopathic & Osteopathic Physicians|Internal Medicine · GURABO, PR · NPI 1013048305
Verified facts
What the public records show
CMS Open Payments records show Jose A Curet Ramos received $1,012.85 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Lokelma, Ozempic, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 934 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 743 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 743 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $432.71 | 42.7% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $196.24 | 19.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.96 | 12.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $114.44 | 11.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.00 | 7.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.50 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,012.85 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $196.24 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $178.70 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $75.82 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.00 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 743 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
934 | 164 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
743 | 134 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
743 | 134 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 2395 | 368 |
| Famotidine | Famotidine | 1955 | 288 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1830 | 308 |
| Synthroid | Levothyroxine Sodium | 1500 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1185 | 190 |
| Simvastatin | Simvastatin | 1065 | 169 |
| Alendronate Sodium | Alendronate Sodium | 1004 | 208 |
| Metoprolol Succinate | Metoprolol Succinate | 979 | 139 |
| Ezetimibe | Ezetimibe | 977 | 156 |
| Farxiga | Dapagliflozin Propanediol | 934 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 872 | 126 |
| Memantine Hcl | Memantine Hcl | 860 | 123 |
| Clopidogrel | Clopidogrel Bisulfate | 842 | 132 |
| Gabapentin | Gabapentin | 818 | 132 |
| Tamsulosin Hcl | Tamsulosin Hcl | 785 | 115 |
| Omeprazole | Omeprazole | 773 | 114 |
| Jardiance | Empagliflozin | 743 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 739 | 125 |
| Metformin Hcl | Metformin Hcl | 679 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 646 | 100 |
| Clonazepam | Clonazepam | 561 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 547 | 95 |
| Lisinopril | Lisinopril | 505 | 71 |
| Cilostazol | Cilostazol | 492 | 102 |
| Fenofibrate | Fenofibrate | 452 | 84 |
| Lansoprazole | Lansoprazole | 418 | 57 |
| Pentoxifylline | Pentoxifylline | 404 | 68 |
| Tradjenta | Linagliptin | 400 | 75 |
| Glyxambi | Empagliflozin/Linagliptin | 390 | 56 |
| Sucralfate | Sucralfate | 389 | 85 |
| Finasteride | Finasteride | 382 | 57 |
| Montelukast Sodium | Montelukast Sodium | 350 | 59 |
| Enalapril Maleate | Enalapril Maleate | 342 | 38 |
| Sertraline Hcl | Sertraline Hcl | 337 | 50 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 316 | 43 |
| Candesartan Cilexetil | Candesartan Cilexetil | 312 | 41 |
| Furosemide | Furosemide | 290 | 55 |
| Carvedilol | Carvedilol | 289 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 289 | 50 |
| Doxazosin Mesylate | Doxazosin Mesylate | 286 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 267 | 65 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 265 | 46 |
| Temazepam | Temazepam | 255 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 34 |
| Irbesartan | Irbesartan | 239 | 35 |
| Eliquis | Apixaban | 226 | 39 |
| Donepezil Hcl | Donepezil Hcl | 222 | 33 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 196 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 193 | 35 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 193 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 191 | 31 |
| Xarelto | Rivaroxaban | 191 | 38 |
| Valsartan | Valsartan | 190 | 36 |
| Trazodone Hcl | Trazodone Hcl | 185 | 36 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 182 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 166 | 32 |
| Nifedipine Er | Nifedipine | 166 | 26 |
| Azithromycin | Azithromycin | 158 | 137 |
| Meclizine Hcl | Meclizine Hcl | 156 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 36 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 140 | 19 |
| Levofloxacin | Levofloxacin | 138 | 119 |
| Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 134 | 109 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 131 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 131 | 32 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 127 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 124 | 112 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 124 | 17 |
| Glimepiride | Glimepiride | 121 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 120 | 105 |
| Rivastigmine | Rivastigmine | 118 | 18 |
| Etodolac Er | Etodolac | 117 | 56 |
| Latanoprost | Latanoprost | 115 | 19 |
| Albuterol Sulfate | Albuterol Sulfate | 109 | 90 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 65 |
| Prednisone | Prednisone | 107 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 18 |
| Ozempic | Semaglutide | 98 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 93 | 41 |
| Pregabalin | Pregabalin | 91 | 28 |
| Spironolactone | Spironolactone | 90 | 18 |
| Atenolol | Atenolol | 88 | 12 |
| Bupropion Hcl | Bupropion Hcl | 88 | 18 |
| Methotrexate | Methotrexate Sodium | 87 | 11 |
| Verapamil Er | Verapamil Hcl | 87 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 86 | 32 |
| Clonidine Hcl | Clonidine Hcl | 84 | 12 |
| Lorazepam | Lorazepam | 84 | 14 |
| Januvia | Sitagliptin Phosphate | 82 | suppressed |
| Nitroglycerin | Nitroglycerin | 82 | 17 |
| Telmisartan | Telmisartan | 82 | 11 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 81 | 18 |
| Trulicity | Dulaglutide | 80 | 13 |
| Bupropion Xl | Bupropion Hcl | 78 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 78 | 68 |
| Humalog | Insulin Lispro | 75 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 13 |
| Mupirocin | Mupirocin Calcium | 70 | 59 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 70 | suppressed |
| Baclofen | Baclofen | 68 | 47 |
| Colchicine | Colchicine | 67 | 15 |
| Diclofenac Sodium Er | Diclofenac Sodium | 66 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 11 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 62 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 57 | suppressed |
| Meloxicam | Meloxicam | 56 | 28 |
| Sildenafil Citrate | Sildenafil Citrate | 56 | suppressed |
| Desonide | Desonide | 52 | 41 |
| Allopurinol | Allopurinol | 49 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 49 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 48 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 14 |
| Memantine Hcl Er | Memantine Hcl | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 45 | suppressed |
| Primidone | Primidone | 45 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 45 | suppressed |
| Alprazolam | Alprazolam | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 32 |
| Gemfibrozil | Gemfibrozil | 40 | 12 |
| Nabumetone | Nabumetone | 40 | 17 |
| Verapamil Hcl | Verapamil Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Sulindac | Sulindac | 38 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 34 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | suppressed |
| Prolia | Denosumab | 35 | 29 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 33 | 24 |
| Jentadueto | Linagliptin/Metformin Hcl | 33 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 22 |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Humulin R | Insulin Regular, Human | 31 | suppressed |
| Mesalamine | Mesalamine | 31 | suppressed |
| Metolazone | Metolazone | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 29 | 22 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | 26 |
| Prednisolone | Prednisolone | 29 | 27 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Loperamide | Loperamide Hcl | 28 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 28 | 25 |
| Synjardy | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 27 | suppressed |
| Ciclopirox | Ciclopirox | 26 | 23 |
| Glipizide | Glipizide | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 24 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 21 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Ofloxacin | Ofloxacin | 22 | 16 |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Clarithromycin | Clarithromycin | 20 | 19 |
| Estazolam | Estazolam | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 19 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | 17 |
| Lumigan | Bimatoprost | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 15 | suppressed |
| Alphagan P | Brimonidine Tartrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 13 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 11 |
| Captopril | Captopril | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Terconazole | Terconazole | 13 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Dilantin | Phenytoin | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,012.85 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, EVENITY, JARDIANCE, LEQVIO, LOKELMA, OTEZLA, Ozempic, PROLIA, REPATHA, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error